Institut Godinot — Clinical Trial Site

108 Registered trials

66 Currently recruiting

Organisation

Institut Godinot

Location

Reims, France

Identifier

ORG-100045736

Address

1 Rue Du General Koenig, 51100, France

Departments

/
033016:
Centre d'oncologie
Clinical Research Unit
Département d’oncologie médicale
Department of Hematology and Medical Oncology
Digestive Oncology
gastroenterology
Hepato-gastroenterology
Hepatogastroenterology
Marne
médecine nucléaire
Medical Oncology
Medical oncology department
N/A
NA
Onco-Urology Department #1503
Oncologie
oncologie Digestive
Oncologie médicale
Oncologue
Oncology
oncology department
Oncology-Radiotherapy
Radiotherapist
Radiotherapy
Service d'hématologie et oncologie Médicale
Service d'Oncologie
Service d'oncologie médicale

Clinical trials at this site (108)

Search interface

Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Metastatic or locally advanced irresectable (stage IV) 4 2025-10-24
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Squamous cell carcinoma of the esophagus 4 2025-10-06
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK… Recruiting

2024-520395-99-00 Advanced solid tumors 7 2025-08-12
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st… Recruiting

2022-501315-13-00 Patients with lateralised oropharyngeal, laryngeal and 5 2025-03-06
Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting

2023-505291-30-01 Triple Negative Breast Cancer with residual disease aft 4 2025-03-06
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Fluoropyrimidine (FP)-naive patients with gastrointesti 4 2025-01-17
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting

2023-506350-21-00 Localized, resected, FIGO stage I (2018 classification) 4 2025-01-06
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 patients with a positive status for molecular residual 5 2024-09-26
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30